ライフサイエンスコーパス: beta-emitter

1 troscopic data (the former isotope is a weak beta emitter).

2 radiated patients, including both gamma and beta emitters.

3 tector and has been optimized for low-energy beta emitters.

4 ss damage to surrounding normal tissues than beta-emitters.

5 dionuclide S values for intermediate-to-high beta-emitters.

6 chosen for the separation of the long-lived beta-emitters (129)I, (36)Cl and the alpha-emitters (154

7 emitters (18)F, (64)Cu, (89)Zr, and (124)I; beta-emitter (131)I; and alpha-particle emitter (225)Ac

8 onoclonal antibodies (mAbs) labeled with the beta-emitters (131)I and (90)Y and the alpha-emitter (21

9 When labeled with the beta-emitters (131)I and (90)Y, HuM195 can eliminate lar

10 approximately 4%-25% for intermediate-energy beta-emitters ((153)Sm, (186)Re, and (89)Sr), and by app

11 ic efficacy of the alpha-emitter (149)Tb and beta(-)-emitter (161)Tb.

12 labeled with 1.5 mCi (1 Ci = 37 GBq) of the beta-emitter 188-Rhenium (188Re) and manifested inhibiti

13 Results using the beta-emitters (188)Re, (177)Lu, and (90)Y and the alpha-

14 , (90)Sr, (103)Ru, (106)Ru, plutonium), pure beta-emitters ((3)H, (14)C, (35)S), gaseous radionuclide

15 and by approximately 11%-30% for high-energy beta-emitters ((32)P, (188)Re, and (90)Y).

16 old therapeutic advantage over the energetic beta emitter 32P.

17 Vascular brachytherapy using pure beta-emitter 32P delivered into a centreing catheter via

18 sites by approximately 4%-23% for low-energy beta-emitters ((33)P, (169)Er, and (177)Lu), by approxim

19 -dichloride, and the second will discuss the beta emitters (89)Sr and (153)Sm-EDTMP.

20 ed to examine the efficacy and safety of the beta-emitter 90-yttrium for the prevention of recurrent

21 ng component of the decay scheme of the pure beta-emitter (90)Y has traditionally been ignored in int

22 With the beta-emitter (90)Y, all of the 10 lymphoma-xenografted m

23 The use of the beta-emitter 90Sr/Y significantly reduced treatment time

24 beta emitters are limited by lower energies and nonspeci

25 chemicals tagged with low-energy electron or beta emitters are the radiopharmaceuticals of choice for

26 t radioactivity concentrations of alpha- and beta-emitters bound to mAbs were compared.

27 e and others have shown that such low-energy beta-emitters can cause cell cycle arrest and apoptosis

28 Intravascular irradiation with beta-emitters has been proposed for inhibition of resten

29 n the clinical setting, the effectiveness of beta-emitters has not been studied in a broad spectrum o

30 radiation therapy, utilizing both gamma and beta-emitters, has been shown to reduce the rate of ISR.

31 We demonstrate that the (177)Lu (beta-emitter) in this fullerene cage is not significantl

32 TheraSphere consists of yttrium-90 (a pure beta emitter) microspheres, which are injected into the

33 Its daughter (99)Tc is a beta emitter of great concern because of its long half-l

34 Because 90Y is a beta emitter, quantitative information from imaging is s

35 For a pure beta -emitter such as (90)Y, marrow dose is usually dete

36 nd their statistical distribution for a pure beta emitter such as 90Y take approximately 1 min on a 3

37 e sparing the bone marrow than are energetic beta emitters such as 32p and 89Sr.

38 e that metabolically incorporated low-energy beta-emitters such as [(35)S]methionine and (3)H-thymidi

39 that metabolic incorporation of a low energy beta-emitter, such as 35S-methionine, can globally influ

40 Because (90)Y is a pure beta-emitter, the requisite safety precautions are not o

41 hecking for a radiotracer that can deliver a beta(-) emitter to the tumor is a fundamental step in th

42 ue, a suitable radiotracer able to deliver a beta- emitter to the tumor has to be identified.

43 tudy require a reevaluation using low-energy beta-emitters to follow not only experimental protocols

44 For beta-emitters, tumors will receive almost entirely nonsp

45 r ZCE025) in combination with long half-life beta(-)-emitters was optimal, yet inadequate as the sole

46 (99)Tc is an artificial beta emitter widely used in nuclear medicine for diagnos

47 n microspheres (SIR Spheres)--containing the beta-emitter, yttrium-90--into the arterial supply of th